Why Summit Therapeutics Stock Tanked Today
An analyst launched coverage of the biotech stock. An analyst's downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. Well before market open that day, Leerink Partners' Daina Graybosch initiated coverage on Summit stock.